If that may come true....
Good products for huge market with management that knowhow to make execution THAN ALL YOU NEED TO GO LONG !!!
The advisor team appointment next to the management team was a brilliant decision. The transformation from a startup company to a viable commercial company is going smooth.
I like MSLP CEO because his driven energy… his ambitions and the professional team next to him would make this company very valuable in the industry.
Frankly, this new management team has done some good progress during the last 6 months.
I bought some shares on last Friday and hopefully to increas my position while the trading volume to increase.
When this event to happen ?
Make your bet.
PDLI with an excellent management team are working diligently to invest in pharmaceutical companies to increase future royalties. Just read the last 3 months press releases….
Mizuho Securities Reiterates Buy on Questcor Pharmaceuticals on Stock Price Weakness
Last update: 26/11/2013 4:47:27 pm
In a report published Tuesday, Mizuho Securities USA analyst Mario Corso reiterated a Buy rating and $93.00 price target on Questcor Pharmaceuticals (NASDAQ: QCOR).
In the report, Mizuho Securities USA noted, "In the wake of today's stock price weakness on short report that FTC will challenge Synacthen deal, we ascertained that QCOR hasn't received a formal FTC inquiry, and anything informal might just be in response to updated HSR guidelines. Even if FTC pursued a court challenge, could take 2+ years to decide, and most recent product case went in favor of acquirer even though products looked more similar than Acthar/Synacthen."